Li-Kuo Su, Editor-in-Chief of Cancer Cell will join us at the Hotel Alimara, Monday 14 January 2013, 09:00 – 10:15, to deliver the 5th in VHIO´s prestigious series of VHIO Meet the Editors talks:
Cancer Cell and the Cancer Research Community
Li-Kuo Su, Editor-in-Chief of Cancer Cell will join us at the Hotel Alimara, Monday 14 January 2013, 09:00 – 10:15, to deliver the 5th in VHIO´s prestigious series of VHIO Meet the Editors talks:
Cancer Cell and the Cancer Research Community
This research studied the action mechanisms of two drugs—lapatinib and trastuzumab—in combination for the treatment of HER2-positive breast cancer. Lapatinib is a molecule which, when combined with trastuzumab, neutralizes the activity of the HER2 receptor and improves the effect of the antibody
During this year´s Annual Meeting of the American Society of Clinical Oncology (ASCO), that came to a close yesterday in…
The Worldwide Innovative Network (WIN) in personalized cancer medicine consortium, of which the Vall d´Hebron Institute of Oncology (VHIO) is…
Officially announced today, Halaven ® (Eribulin) has received reimbursement approval from the Spanish Directorate General of Pharmacy and Health Products,…
The Prize, supporting translational research of excellence, was established in memory of the pioneer of cancer research in France, Georges…
Bioinformatics Barcelona (BIB), launched in 2014, constitutes a regionally-based multi-center bioinformatics platform as part of a joint initiative of the…
Taking place on Monday 29 June 2015, 15:00 – 16:15, we are delighted to announce that Senior Editor of Nature Reviews Cancer,…
The study, led by VHIO, is the first to use gene expression to classify fibroepithelial tumors Genomic discovery reveals decisively…
Clinical research carried out as a phase I study shows that immunotherapy is safe and effective in reducing the size…
A study by the Vall d’Hebron Institute of Oncology (VHIO) demonstrates that by combining drugs which had already been used previously, but became ineffective, they boost each other’s efficacy and at the same time overcome the resistance developed by the patient to each individual drug. This strategy could offer an unprecedented key to multiplying treatment options.
At the recent annual San Antonio Breast Cancer Symposium (SABCS), 8 – 12 December, San Antonio, USA, the ecancerTV team…
A special study visit was jointly organized by the Centre of Genomic Regulation (CRG) and the European Molecular Biology Laboratory (EMBL) as partners of the EU CommHERE Communicating European Health Research Network, in collaboration with the European Union of Science Journalists’ Associations (EUSJA)
Each year, in January, the Spanish periodical EL MUNDO publishes its selection of the 500 most influential Spanish citizens for that…
In two recent interviews with ecancer Josep Tabernero highlights key studies and promising data presented at the ESMO 14th World Congress on Gastrointestinal Cancer (WCGC), Barcelona, 27 – 30 June 2012, as well as discusses the WIN Consortium (Worldwide Innovative Networking in personalized cancer medicine) launch of WINTHER: The WIN therapeutics clinical trial.